Study to Demonstrate the Bioequivalence of Single Oral Administration of K-001 Relative to Single Oral Coadministration of Separate Tablets of K-877-ER and CSG452
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Kowa Research Institute, Inc.
Age
18–45
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Participant provides written informed consent before any study-specific evaluation is performed.
Participant is a healthy adult male or female volunteer between the ages of 18 and 45 years, inclusive, at Screening.
Participant has a body mass index of 18 to 30 kg/m2, inclusive, at Screening.
You may not be if
Participant has clinically significant abnormalities at Screening or at Check-in assessments, in the opinion of the investigator.
Participant is pregnant or breastfeeding or intends to become pregnant within 30 days after the last dose of study drug.
Clareo Health | Study to Demonstrate the Bioequivalence of Single Oral Administration of K-001 Relative to Single Oral Coadministration of Separate Tablets of K-877-ER and CSG452
